Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated

Apellis Pharmaceuticals, Inc.

Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.
Cowen will receive up to 3.0% commission on gross proceeds from sales.
ATM offering made under existing shelf registration statement (File No. 333-269899).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apellis Pharmaceuticals, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC valued at up to $300.0 million (effective 2023-10-31).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $300.0 million
Effective: 2023-10-31

Exact text from the filing

In connection with the entry into the Agreement, on October 31, 2023, the Company terminated its prior Open Market Sale Agreement SM , dated as of January 20, 2022 (the “Prior Agreement”), by and between the Company and Jefferies LLC (“Jefferies”), in accordance with its terms.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apellis Pharmaceuticals, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-01).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: up to $300.0 million
Effective: 2023-11-01

Exact text from the filing

On November 1, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with Cowen and Company, LLC, as agent (“Cowen”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Shares”), from time to time through Cowen (the “Offering”).

View on SEC.gov

767 material agreements filed in the last 30 days. Browse all material agreements →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-267745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.